Rate My Professor Christopher Cardwell

Professor Christopher Cardwell is a Professor in the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, affiliated with the Centre for Public Health. His research specializations include pharmacoepidemiology, focusing on the impact of medications on cancer risk and survival. He conducts statistical analyses for randomised controlled trials, prognostic models, systematic reviews, and meta-analyses. Studies by Cardwell have examined medications such as statins, aspirin, proton pump inhibitors, hormone replacement therapy, and antibiotics in relation to cancers including breast, gastroesophageal, and gastric cancers. Previously, he served as a Cancer Research UK Postdoctoral Research Fellow at Queen's University Belfast.

Cardwell was shortlisted for the 2021 Vice-Chancellor’s Research Prizes competition in the Research Engagement category for Project Daire. He has given invited talks, including 'Supporting advance care planning in dementia palliative care' and 'Evaluation of the family carer decision support intervention' in 2018, 'Commonly used medications and cancer survival' at Tilburg University in 2016, 'Breast Cancer Survival and Use of Propranolol, Statins and Digoxin' at Vanderbilt University in 2015, and presentations on resources in Northern Ireland at the European Cancer Pharmacoepidemiology meeting in 2013. Key publications include 'Antidepressant and anxiolytic medications and risk of mortality in people with dementia: a nested case-control study in Northern Ireland' (2026, Journal of Alzheimer's Disease), 'Dental caries prevalence among Dubai and Northern Emirates public schoolchildren: an epidemiological retrospective study (2015-2019)' (2026, International Journal of Paediatric Dentistry), 'House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland' (2026, Breast Cancer Research and Treatment), 'Rate of MGUS progression to haematological malignancies: a systematic review' (2026, European Journal of Haematology), 'Antibiotic use and survival from breast cancer: a population-based cohort study in England and Wales' (2025, Nature Communications), and 'Statin use after diagnosis of breast cancer and survival: a population-based cohort study' (cited by 126).